AWY

~{N}-[2-(7-methoxynaphthalen-1-yl)ethyl]ethanamide


Toggle HydrogenToggle Labels

Chemical Component Summary

Name~{N}-[2-(7-methoxynaphthalen-1-yl)ethyl]ethanamide
Identifiers~{N}-[2-(7-methoxynaphthalen-1-yl)ethyl]ethanamide
FormulaC15 H17 N O2
Molecular Weight243.301
TypeNON-POLYMER
Isomeric SMILESCC(=O)NCCc1cccc2c1cc(cc2)OC
InChIInChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
InChIKeyYJYPHIXNFHFHND-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count35
Chiral Atom Count0
Bond Count36
Aromatic Bond Count11

Drug Info: DrugBank

DrugBank IDDB06594 
NameAgomelatine
Groups
  • approved
  • investigational
DescriptionAgomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. The Committee for Medical Products for Human Use (CHMP) recommended refusal of marketing authorization on 27 July 2006. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.
Synonyms
  • Agomelatina
  • Agomelatine
Brand Names
  • Thymanax
  • Valdoxan
IndicationAgomelatine is indicated to treat major depressive episodes in adults.
Categories
  • Acetates
  • Acids, Acyclic
  • Amides
  • Antidepressive Agents
  • Central Nervous System Agents
ATC-CodeN06AX22
CAS number138112-76-2

Drug Targets

NameTarget SequencePharmacological ActionActions
5-hydroxytryptamine receptor 2CMVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPD...unknownantagonist
Melatonin receptor type 1AMQGNGSALPNASQPVLRGDGARPSWLASALACVLIFTIVVDILGNLLVIL...unknownagonist
Melatonin receptor type 1BMSENGSFANCCEAGGWAVRPGWSGAGSARPSRTPRPPWVAPALSAVLIVT...unknownagonist
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknownsubstrate
Cytochrome P450 2C9MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...unknowninhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL10878
PubChem 82148
ChEMBL CHEMBL10878
ChEBI CHEBI:134990
CCDC/CSD KAXSEJ, FAFGOL01, KAXSIN, OTAQIK, FAFGOL, WERNOW03, OTAQEG, KAXSOT, FAFGOL02, FAFGOL03, FAFGUR, WERNOW, KAXSUZ, FAFHEC, WERNOW02, WERNOW01, WERNOW04
COD 4505886, 4505887, 4500184, 4505888, 2108512, 2108513, 2009809, 4505889, 4500185